Allergan acquires neurotoxin specialist Bonti in $195m deal

In particular, following the completion of the acquisition Allergan will obtain the global rights to the experimental EB-001A and AB-001T programmes being developed for both therapeutic and aesthetic use.

The deal, which involves an upfront payment of $195 million and additional payments in connection with future commercial milestones, will act to expand Allergan’s portfolio of injectable facial treatments.

"We're excited about the development and commercial prospects for our novel programs within Allergan's leading Medical Aesthetics portfolio," commented Fauad Hasan, CEO and co-founder at Bonti. "The promise of benefitting more consumers worldwide with our novel neurotoxin programs plus Allergan's stature and resources in this market will help realize our team's and investors' aims. We could not envision a more compelling acquirer or better strategic fit"

In the US alone there is huge potential for faster acting shorter-duration facial injectable treatments with an estimated 65 million customers considering such cosmetic procedures.

"The acquisition of Bonti is a strategic investment for the future of our Medical Aesthetics business and has the potential to enhance our best-in-class Medical Aesthetics pipeline," said Brent Saunders, Chairman and CEO of Allergan. "With the Medical Aesthetics market vastly expanding, a fast-acting neurotoxin with a 2 to 4-week duration will be an attractive option for consumers, particularly those who are considering a Medical Aesthetics treatment for the first time."

Louis Goss

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.